Nova Eye Medical Announces U.S. Market Clearance of the iTrack™ Advance Canaloplasty Device

FREMONT, Calif.--(BUSINESS WIRE)--Nova Eye Medical Limited (ASX: EYE) (Nova Eye Medical or the Company), a medical technology company committed to advanced ophthalmic treatment technologies and devices, today announces that it has been granted U.S. Food and Drug Administration (FDA) 510(k) clearance for its new canaloplasty device, iTrack™ Advance. The iTrack™ Advance has been cleared for microcatheterization and viscodilation to reduce intraocular pressure (IOP) in adult patients with primary